Since virus immunotherapies have the potential to improve therapy responses, we established a platform technology based on Herpes Simplex Virus Type 1 (HSV1). TheraVision constitutes a complete development pipeline including a proprietary HSV1 engineering vector for the modular integration of transgenes, a GMP-compliant production process, and complex preclinical test systems including human tumour and immune cells to demonstrate sensitivity and safety.